RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. by Cabrales, Pedro
UC San Diego
UC San Diego Previously Published Works
Title
RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on 
Cancer Cells and SIRP-α on Monocytes/Macrophages.
Permalink
https://escholarship.org/uc/item/1r3988bk
Journal
Translational oncology, 12(4)
ISSN
1936-5233
Author
Cabrales, Pedro
Publication Date
2019-04-01
DOI
10.1016/j.tranon.2018.12.001
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
R
M
D
C
M
P
D
D
In
C
im
su
co
re
re
pr
to
C
ch
an
bi
ag
pr
www.transonc.com
Trans la t iona l Onco logy Volume 12 Number 4 April 2019 pp. 626–632 626Rx-001 Acts as a Dual Small
olecule Checkpoint Inhibitor by
ownregulating CD47 on Cancer
ells and SIRP-α on Monocytes/
acrophagesac
sy
th
ch
cl
Ad
U
E-
Re
©
art
19
htedro Cabrales
epartment of Bioengineering, University of California San
iego, 9500 Gilman Dr., La Jolla, CA 92093, USAAbstract
RRx-001 is a pleiotropic anticancer agent in phase III clinical trials, which polarizes tumor-associated macrophages
from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype. One of the ways in which tumors
promote M2 polarization and evade macrophage-mediated destruction is through upregulation of CD47 expression.
As a myeloid-specific immune checkpoint, CD47 interacts with signal-regulatory protein alpha (SIRPα) on
macrophages and monocytes to prevent phagocytosis. Herein, the effect of RRx-001 on CD47 and SIRPα
expression was evaluated as well as its activity in vivo in macrophage-depleted tumors. In vitro, RRx-001 was found
to decrease the expression levels of CD47 and SIRPα on tumor cells and monocytes/macrophages, respectively,
reducing the phagocytosis inhibitory function of the CD47/SIRPα interaction. In vivo, macrophage depletion by
clodronate in an A549 xenograft-bearing mouse model attenuated the ability of RRx-001 to suppress tumor growth,
which suggests that the presence of infiltrated macrophages in the tumor microenvironment is a sine qua non
condition for the antitumor activity of RRx-001. Furthermore, these in vitro effects translate into significant antitumor
activity in mouse models of lung cancer. Importantly, unlike anti-CD47 antibodies, RRx-001, which has been
evaluated in close to 300 patients in 9 clinical trials, is not associated with any hematologic toxicities. On the basis of
demonstrated antitumor activity and minimal toxicity in phase II clinical trials, RRx-001 has received clearance from
the FDA and the EMA for phase III, multicenter studies in subjects with relapsed/refractory solid tumors.
Translational Oncology (2019) 12, 626–632dress all correspondence to: Pedro Cabrales, Department of Bioengineering,
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D47 (cluster of differentiation 47) is a glycoprotein of the
munoglobulin superfamily that is ubiquitously present on the
rface of all cells, particularly tumors cells where its overexpression
rrelates with poor prognosis. The engagement of CD47 with signal
gulatory protein-alpha (SIRPα) expressed on myeloid cells is
ferred to as an innate immune checkpoint1 because it functions to
event macrophage phagocytosis and render tumor cells less sensitive
innate immune surveillance.2,3 In light of the overexpression of
D47 on cancer cells and its identification as an innate immune
eckpoint, several CD47 targeted therapies including anti-CD47
tibodies, engineered receptor decoys, anti-SIRPα antibodies, and
specific agents have been developed.4 Since CD47/SIRPα blocking
ents “release the brakes” on phagocytosis, antigen uptake,
ocessing, and presentation are increased, which, in turn, stimulatesquired responses and links the innate and adaptive immune
stems.5 CD47/SIRPα blocking therapies may therefore enhance
e anticancer effects of anti–PD-1, PD-L1, and CTLA-4 immune
eckpoint inhibitors that target T-cell activation.
RRx-001, an anticancer agent with clearance to start phase III
inical trials, pleiotropically targets tumor-associated cells including
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Translational Oncology Vol. 12, No. 4, 2019 RRx-001 as a Dual Small Molecule Checkpoint Inhibitor Cabrales 627acrophages and cancer stem cells.6 The aim of these studies was to
aluate the effects of RRx-001 on CD47 expression and its
teraction with SIRPα as well as macrophage-mediated phagocytosis
human tumor cells and downstream effects on c-myc and cancer
em cells. The experiments are described below.
aterials and Methods
thics Statement
All protocols were approved by the Institutional Animal Care and
se Committee of the University of California, San Diego, and
nducted according to the Guide for the Care and Use of Laboratory
nimals (US National Research Council, 2011).
ice Management
Female BALB/c nude mice (19.2 ± 1.7 g) were subcutaneously
jected with 5 × 106 of A549 cells suspended in PBS and containing
%MatrigelMatrix (Coining, 354234) to establishNSCLC xenograft
odels. Tumor-bearing mice were randomized into four cohorts after
mors had a volume ∼100 mm3. RRx-001, supernatant, and vehicle
ere intraperitoneal injected twice a week and once a day respectively.
umor volume was calculated as length × width × width/2.
eagents
All reagents were purchased Sigma-Aldrich. LysoTracker and
itoSox were purchased from Invitrogen. The primary antibodies
ed for Western analyses were purchased as follows: anti-LC3 (Cell
gnaling Technology, 3868), anti–β-actin (Cell Signaling Technol-
y, 3700), anti–caspase 9 (Cell Signaling Technology, 9502), anti–
spase 3 (Cell Signaling Technology, 9665), B-actin, rabbit
onoclonal (Cell Signaling Technology), anti-CD47 (rabbit poly-
onal; GeneTex), and anti–SIRP-α (rabbit polyclonal; GeneTex).
ell Lines and Culture
The following human cell lines were purchased from American Type
ulture Collection (Manassas, VA): MCF-7 (breast adenocarcinoma,
eural effusion), AU-565 (adenocarcinoma, breast), HBL-100 (breast
ithelial cells with transformed morphology), and MDA-MB-231
denocarcinoma). The cell culture medium used was RPMI 1640 (Life
echnologies, Inc., Grand Island, NE) supplemented with 10%
tal bovine serum (Hyclone, Logan, UT), 100 U/ml penicillin and
0 μg/ml streptomycin (Life Technologies, Inc.), and 10 μg/ml
profloxacin. All cell lines used in the study were free frommycoplasma.
ell Viability Assays
Cells (approximately 5000 cells/well) were seeded into a 96-well
ate and treated with variable concentrations of RRx-001 for
hours. Subsequently, the cells were labeled using a Cell Counting
it-8 (CKK8) for 2 hours. Absorbance at 450 nm was measured with
plate reader, and cell viability was expressed as the percentage of the
sorbance of treated cells versus untreated cells.
ouse Bone Marrow–Derived Macrophage (BMDM)
reparation
Mouse macrophages were obtained from 8- to 10- week-old mouse
ne marrow. Briefly, mice were euthanized, and femurs and tibiae
ere isolated. The bones were kept in ice-cold PBS and sterilized in
% ethanol. By flushing them with mouse macrophage medium
MDM with 10% FBS, 1× penicillin/streptomycin, 250 mM
utamine, and 25 mM HEPES, all from Corning Inc.), bonearrow cells were gathered and plated at 1 × 107/ml in 25-mm Petri
shes in mouse macrophage medium.
acrophage Polarization Procedure
BMDMs were generated by isolating bone marrow from femurs
d culturing in high-glucose Dulbecco's modified Eagle's medium
yclone, Logan, UT) containing 10% (vol/vol) fetal bovine serum
ibco) with macrophage colony-stimulating factor (15 ng/ml;
protech) at 37°C with 5% CO2. Medium was replaced with
esh medium containing IL-4 (10 ng/ml) and IL-10 (20 ng/ml) to
tain M2 polarized BMDM, or with fresh medium containing IFN-
mma (20 ng/ml) and LPS (100 ng/ml) to obtain M1 polarized
MDM 24 hours. M0, M1, or M2 polarized BMDMs were
cubated with vehicle or 2 μM RRx-001 for 24 hours. Phagocytosis
A549 cells by polarized M0, M1, or M2 macrophages treated with
μM RRx-001 or the supernatant of previously treated cells with
μM RRx-001 for 4 hours. Phagocytic index indicated the number
A549 cells phagocytosed per 100 macrophages.
uclear Fractionation and Western Blotting
Cell lysates containing extracted proteins were separated on 10%
S-polyacrylamide gels and transferred to nitrocellulose mem-
anes. Membranes were blocked at room temperature for 1 hour in
fat-free milk and incubated overnight at 4°C with a primary
tibody followed by incubation with the appropriate conjugated
porter antibody for 1 hour at room temperature.
ytokine Assay
Analysis of cytokines and chemokines in macrophage culture
pernatants was performed in the Mouse 26-plex kits purchased
om Affymetrix (Santa Clara, CA) and used according to the
anufacturer's recommendations. Briefly, samples were mixed with
tibody-linked polystyrene beads on 96-well filter-bottom plates and
cubated at room temperature for 4 hours followed by overnight
cubation at 4°C. Room temperature incubation steps were performed
an orbital shaker at 400 rpm. Plates were vacuum-filtered, washed
ice with wash buffer, and then incubated with biotinylated detection
tibody for 2 hours at room temperature. Samples were then filtered
d washed twice as above and resuspended in streptavidin-PE. After
cubation for 1 hour at room temperature, two additional vacuum
ashes were performed, and the samples were resuspended in reading
ffer. Samples were measured in duplicate.
NA Extraction and qRT-PCR
Total cellular RNA was extracted with the TRIzolreagent (Invitro-
n, USA), and cDNA was synthesized by using M-MLV reverse
anscriptase (Life Technologies). Real-time PCR was performed with
BR Green master mix (Applied Biosystems). To normalize the
ount of total RNA in each reaction, β-actin cDNA was used as an
ternal control. Results are expressed as relative abundance. The purity
the amplified products was validated by the dissociation curve.
low Cytometry Analysis
Antibody Preparation, Flow Cytometry Analysis, and Cell Sorting. The
tihCD47 (B6H12) hybridoma was obtained from the ATCC.
ybridoma cells were cultured under standard conditions, and
tibodies were purified by Protein G. For quantification of CD47
pression, cells were labeled with a saturating concentration of a 1:1
ycoerythrin-conjugated anti-CD47 antibody (BD Pharmingen) and
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Figure 1. In the presence of RRx-001 and supernatant, CD47 and
SIRPα levels are decreased.
628 RRx-001 as a Dual Small Molecule Checkpoint Inhibitor Cabrales Translational Oncology Vol. 12, No. 4, 2019alyzed using a BD LSR Fortessa Analyzer. Tumor cells were
cubated with 20 μM CFDA-SE using a Vybrant CFDA-SE Cell
racer Kit (Invitrogen). Macrophages were incubated in serum-free
edium for 2 hours with anti-CD11b APC-eFluor 780 (eBioscience)
fore the adding 2 × 105 of CFDA SE-labeled tumor cells.
acrophages and tumor cells were incubated for 2 hours, and
bsequently, cells were washed twice. Gates were placed according to
stained and fluorescence-minus-one controls. Fluorescently labeled
tibodies targeting macrophage and tumors were used. Macrophages
at had successfully phagocytized tumor cells were positive for eFluor
0 and CFDA-SE stain. BD QuantiBRITE PE beads (BD
harmingen) were analyzed at the same settings and conditions as the
mples. Median absolute CD47 antibody binding for each sample was
termined from a calibration curve constructed from the Quanti-
RITE bead data using the FlowJo Data Analysis software calibration
ol. BMDMs were trypsinized and incubated with phycoerythrin-
beled antibodies against mouse F4/80, CD80, and CD86 for
minutes on ice; washed with PBS; and analyzed using a FlowJo
ata Analysis software calibration tool.
Vitro Phagocytosis Assay
Briefly, 1 × 105 macrophages were planted per well in glass-
ttom cell culture dishes. According to the manufacturer's protocol,
549, MCF-7, AU-565, HBL-100, or MDA-MB-231 cells were
beled with 20 μM CFDA-SE using a Vybrant CFDA-SE Cell
racer Kit (Invitrogen). Macrophages were incubated in serum-free
edium for 2 hours before the adding 2 × 105 of CFDA SE-labeled
mor cells. Macrophages were repeatedly washed and subsequently
aged with confocal microscope. The phagocytic index was
lculated as the number of phagocytosed carboxyfluorescein
ccinimidyl ester (CFSE)–positive cells per 100 macrophages.
Vivo Treatment with A549 Xenografts and Clodrolip/
lodronate
Dichloromethylene diphosphonate (clodronate, 2.5 g; Sigma) was
capsulated in liposomes formed by a 25:1 w/w ratio of phosphatidyl-
oline:cholesterol (Sigma), and the resulting liposomes were resus-
nded in 4 ml sterile PBS. Clodronate liposomes for syngeneic transfer
periments were synthesized or purchased from ClodronateLiposomes.
g (the Netherlands). Mice bearing A549 were anesthetized by IP
jection of 100 mg/kg ketamine and 10 mg/kg xylazine, and 50 μl of
hicle or clodronate-containing liposomes was injected. IV administra-
on of clodronate depleted macrophages.
tatistical Analysis
Values are expressed as means ± SD and were obtained from at least
ree independent experiments. Statistical analyses were performed
ing GraphPad. Student's t test (two-tailed) or one-way ANOVA
as performed to determine significance when comparing data from
fferent treatment groups. P values were calculated, and P b .05 was
nsidered to represent significant difference.
esults
reatment with RRx-001 and the Supernatant of RRx-001–
reated Macrophages Downregulates CD47 on Tumor Cells
d SIRPα on Macrophages
To determine whether RRx-001 dually downregulates CD47 and
RPα at the protein level, 1 × 105 A549 cells and 1× 104 A549
acrophages were plated per well, incubated with 2 μM RRx-001,d analyzed with Western blotting. RRx-001 was shown to decrease
e protein levels of CD47 and SIRPα compared to control (no
eatment). A less dramatic reduction in CD47 and SIRPα levels
curred with the supernatant of RRx-001–treated macrophages, as
own in Figure 1. The decrease of CD47 and SIRPα expression
ggests that RRx-001 disrupts CD47-SIRPα interaction, leading to
agocytosis.
reatment with RRx-001 Polarizes Macrophages from an M2
henotype to M1
In the tumor microenvironment, macrophages are able to
namically switch between two distinct phenotypes: M1 classically
tivated macrophages, which are proinflammatory and antitumor,
d M2 alternatively activated macrophages, which are anti-
flammatory and immunosuppressive.7 Based on clinical biopsies,
Rx-001 has been shown to reorient or reprogram M2 tumor-
sociated macrophages (TAMs) to the M1 phenotype.8
BMDMs from C57/BL6 mice were incubated with IL-4 (10 ng/ml)
d IL-10 (20 ng/ml) for 24 hours to polarize them to an M2
enotype. CD80 and CD86 were selected as M1 macrophage
arkers, and CD206 and CD163 as M2 macrophage markers.9
These M2-polarized BMDM were then incubated with vehicle or
μM RRx-001 for 24 hours. The mRNA expression levels of M1
arkers CD80 and CD86 were found to significantly increase with
Rx-001 treatment compared to vehicle control (Figure 2).
The mRNA expression levels of M1 markers, CD80 and CD86, as
termined by reverse transcription–quantitative polymerase chain
action, were significantly increased with RRx-001 treatment, as
own on the box-and-whisker plot. These data indicate that RRx-
1 preferentially polarizes macrophages to an M1 phenotype. Data
e mean ± SD for three independent experiments.
Rx-001, the Supernatant of Previously RRx-001–Treated
acrophages, and RRx-001-Cys-Ox Reduce the Expression of
D47 and SIRPα on A549 Cells
Previous work on the metabolites of RRx-001 has identified an
idized cysteine adduct with anticancer activity. This adduct is
ferred to as RRx-001-Cys-Ox.
R
M
O
th
w
ca
ph
D
or
R
ce
A
m
dr
co
m
tr
im
in
th
ac
ph
m
ph
A
re
Sc
C
ph
m
in
lin
R
ca
de
us
R
M
A
R
ov
in
to
se
ph
H
pr
in
8
of
ph
m
Figure 3. RRx-001 and the supernatant of previously RRx-001–
treated macrophages promote in vitro phagocytosis of A549 cells.
Figure 2. RRx-001 polarizes M2 macrophages to an M1 phenotype.
Translational Oncology Vol. 12, No. 4, 2019 RRx-001 as a Dual Small Molecule Checkpoint Inhibitor Cabrales 629Rx-001 and the Supernatant of Previously RRx-001–Treated
acrophages Promote the Phagocytosis of CD47-
verexpressing A549 Cells
Blocking CD47 with anti-CD47 monoclonal antibodies leads to
e phagocytosis of cancer cells.10 On this basis, it was investigated
hether RRx-001 would enhance the phagocytosis of A549 lung
ncer cells. Macrophages derived from mouse bone marrow cells
agocytosed A549 cells at a low frequency when treated with 0.1%
MSO vehicle. However, treatment with 2 μM and 5 μM RRx-001
the supernatant of previously treated cells with 2 μM and 5 μM
Rx-001 for 2 hours significantly increased the phagocytosis of A549
lls (Figure 3). Incubation for 8 hours of human breast cancer cells
U-565, MCF-7, and MDA-MDB-231 that overexpress CD47 and
ouse bone marrow macrophages in the presence of 2 μM RRx-001
amatically increased the phagocytosis of the cancer cells vs. vehicle
ntrol (Figure 4).
CFSE-labeled lung cancer A549 cells were incubated with mouse
acrophages and 2 μM RRx-001 or the supernatant of previously
eated cells with 2 μM RRx-001 for 2 hours and examined by
munofluorescence microscopy to detect phagocytosis. Phagocytic
dex, represented on the box-and-whisker chart, was calculated as
e mean number of A549 cells phagocytized per 100 macrophages
cording to the following formula: phagocytic index = number of
agocytized A549 cells/100 macrophages. The error bars represent
ean ± SD (n = 3).
Flow cytometric analysis of eFluor-labeled bone marrow macro-
ages were incubated at 37°C with CFSE-labeled breast cancer cells
U-565, MCF-7, and MDA-MDB-231. The percentage value
presents the proportion of phagocytic cells. Mean ± SD (n = 3).
attergram was generated by combining eFluor fluorescence with
FSE fluorescence, and the double-positive population (indicating
agocytosis of CFSE-labeled cancer cells by eFluor 670–labeled
acrophages) is shown in the upper right quadrant. FACS analysis
dicated the presence of CD47 in breast cancer cells (Figure 4). Cell
es used in this study showed abundance of CD47. Exposure to
Rx-001 induced apoptosis in breast cancer. Incubation of breast
ncer cells with RRx-001 increased annexin V binding in a dose-
pendent manner. The percentage of annexin V–positive cells was
ed to determine the decree of apoptosis.Rx-001 and the Supernatant of Previously RRx-001–Treated
acrophages also Promote M2 Macrophages to Phagocytose
549 Cells
The same in vitro phagocytosis assay was used to evaluate whether
Rx-001 induced mouse M2 macrophages to phagocytose CD47-
erexpressing A549 cells. BMDMs from C57/BL6 mice were
cubated with IL-4 (10 ng/ml) and IL-10 (20 ng/ml) for 24 hours
polarize them to an M2 phenotype. CD206 and CD163 were
lected as M2 macrophage markers. M2 macrophages did not
agocytose tumor cells when treated with 0.1% DMSO vehicle.
owever, treatment with 2 μM RRx-001 or the supernatant of
eviously treated cells with 2 μM RRx-001 for 2 hours significantly
creased the phagocytosis of A549 cells (Figure 5). Incubation for
hours with A549 cells and M2-derived macrophages in the presence
2 μM RRx-001 and supernatant significantly increased the mean
agocytosis rate of the M2 macrophages. The error bars represent
ean ± SD (n = 3).
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Figure 4. RRx-001 increases phagocytosis of breast cancer cells by bone marrow macrophages.
630 RRx-001 as a Dual Small Molecule Checkpoint Inhibitor Cabrales Translational Oncology Vol. 12, No. 4, 2019AMDepletion with Clodronate or Clodrolip Attenuates RRx-001
ntitumor Activity in A549 Xenografts
To determine whether the anticancer activity of RRx-001 on the
549 lung cancer model is dependent on the presence of TAMs in
mor tissue, A549-bearing nude mice were randomized into five
oups (n = 4 per group), as follows:
1. IV clodrolip: 0.5 g/kg clodrolip (clodronate emulsion)
2. IV clodrolip + IV RRx-001: 0.5 g/kg clodrolip and 10 mg/kg
of RRx-001gure 5. RRx-001 and the supernatant of previously RRx-001–treated m
d M2 macrophages.3. IP 1 g/kg clodronate in PBS
4. IV RRx-001
5. Control: no treatment
The results from the experiment are shown in Figure 6. Treatment
ith RRx-001 resulted in the most significant tumor growth
tardation, followed by clodrolip + RRx-001, clodrolip alone, and
odronate alone, both of which reduced tumor progression through
acrophage depletion. These data indicate that reduction of residentacrophages promote in vitro phagocytosis of A549 cells by M0
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Figure 6. Clodronate-induced macrophage elimination attenuates the anticancer activity of RRx-001 in A549 cells.
Translational Oncology Vol. 12, No. 4, 2019 RRx-001 as a Dual Small Molecule Checkpoint Inhibitor Cabrales 631acrophages in tumor-bearing mice attenuates the antitumor activity
RRx-001.
onclusion
lsewhere, it has been demonstrated that RRx-001 polarizes M0 and
2 macrophages to the M1 phenotype.11,12 To dissect the
echanism by which RRx-001 skews macrophage differentiation
d stimulates phagocytosis, its effect on the expression of CD47 and
RPα was examined since disruption of the CD47-SIRPα axis is
own to promote M1 polarization.13
These experiments identify an RRx-001–dependent surface
crease of CD47 on tumor cells and of SIRPα on macrophages.
ather than a CD47 or SIRPα blocking antibody, which is associated
ith platelet aggregation, red blood cell hemagglutination,14 and
se-limiting hemolytic anemias,15 RRx-001 is a well-tolerated,
inimally toxic, and nonmyelosuppressive small molecule that
wnregulates the CD47-SIRPα axis and is not associated with
molytic anemia.
Within the tumor microenvironment, macrophages, which are
undant,16 acquire two opposing phenotypes: proinflammatory,
titumor M1 and anti-inflammatory, protumor M2.17 To subvert
1 macrophage–mediated cytotoxicity, cancer cells overexpress the
ll surface receptor CD47, which binds to its counter-receptor,
RPα, on myeloid cells; this interaction serves as a primary
gulatory checkpoint18 through the delivery of an inhibitory “do
t eat” antiphagocytosis signal. CD47 upregulation, which has been
ported in multiple solid and hematological malignancies as well as
ncer stem cells,19 correlates with poor clinical outcomes.20
Herein, the effect of RRx-001 on malignant cells was examined in
tro and in vivo; in addition, the effect of the supernatants of
acrophages either treated or not with RRx-001 was evaluated. In
tro studies demonstrate that RRx-001 and supernatant promote
acrophage-mediated phagocytosis of tumor cells. In vivo studies
monstrate that RRx-001 potently inhibits antitumor growth in
eclinical xenograft models; this inhibitory effect is diminished when
AM density is depleted with clodronate.Collectively, these data support the conclusion that RRx-001 is a
inimally toxic dual checkpoint inhibitor of CD47 and SIRPα that
imes macrophages both in vitro and in vivo to attack cancer cells
d suggest the potential for enhanced antitumor efficacy in
mbination with immune checkpoint inhibitors and other
munotherapies.
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